Filtered By:
Therapy: Hormonal Therapy

This page shows you your search results in order of date. This is page number 14.

Order by Relevance | Date

Total 218 results found since Jan 2013.

Menopausal hormone therapy use in 17 European countries during the last decade
The first ‘Women's Health Initiative’ (WHI) randomised controlled trial assessed use of continuous combined menopausal hormone therapy (cc-MHT). It was prematurely stopped because of an increased invasive breast cancer (BC), coronary heart disease (CHD), stroke and pulmonary embolism risk. Consequently, scientific societies recommended use of MHT at the lowest effective dose for the shortest duration. As a result, a sharp decline in MHT use occurred worldwide.
Source: Maturitas - August 4, 2014 Category: Primary Care Authors: Lieveke Ameye, Caroline Antoine, Marianne Paesmans, Evandro de Azambuja, Serge Rozenberg Source Type: research

Growth Hormone in Adults With Growth Hormone DeficiencyGrowth Hormone in Adults With Growth Hormone Deficiency
What are the long-term effects of growth hormone therapy on risk of cardiovascular disease, fractures, cancer, and stroke? Clinical Endocrinology
Source: Medscape Diabetes Headlines - July 18, 2014 Category: Endocrinology Tags: Diabetes & Endocrinology Journal Article Source Type: news

New method may allow breast cancer drug to be given through skin
Endoxifen, a drug that has proven effective in the prevention and treatment of breast cancer, but with serious side-effects, may be delivered effectively through the skin using a new topical drug-delivery system. Endoxifen, one of the most commonly used hormone therapy for breast cancer, has also been shown to prevent the disease. However, taken orally, the drug can cause side-effects such as hot flashes and vaginal atrophy, along with increased risk of endometrial cancer and stroke, that leave it wanting as a routine method of chemoprevention.
Source: ScienceDaily Headlines - July 10, 2014 Category: Science Source Type: news

Stroke prevention in women: synopsis of the 2014 american heart association/american stroke association guideline.
Abstract DESCRIPTION: In February 2014, the American Heart Association/American Stroke Association released their first guideline focused on stroke prevention in women. This new guideline highlights unique risk factors for stroke in women, including oral contraception and hormone therapy, and pregnancy-associated disorders, such as preeclampsia, that may have long-lasting consequences on a woman's health. It also addresses hypertension; atrial fibrillation; migraine headache with aura; and the epidemiology of types of stroke, such as aneurysmal subarachnoid hemorrhage and cerebral vein thrombosis, that are predomi...
Source: Annals of Internal Medicine - June 17, 2014 Category: Internal Medicine Authors: Bushnell C, McCullough L Tags: Ann Intern Med Source Type: research

Menopausal hormone therapy has risks and benefits during the intervention and poststopping phase
This report summarises the previous WHI reports alongside 13 years of follow-up in 81.1% of surviving participants. Some selection bias may have occurred in the postintervention phase due to occurrences in the intervention phase. Methods Women were recruited from 1993 to 1998...
Source: Evidence-Based Medicine - May 19, 2014 Category: Internal Medicine Authors: Warren, M. P. Tags: Clinical trials (epidemiology), Epidemiologic studies, Drugs: cardiovascular system, Stroke, Hypertension, Menopause (including HRT), Ischaemic heart disease, Venous thromboembolism, Pulmonary embolism, Injury Prevention Source Type: research

Hormone replacement therapy in menopause
Embora o estrógeno já esteja disponível para venda há mais de seis décadas, as mulheres ainda permanecem confusas quanto ao risco e aos benefícios da terapia hormonal na menopausa (THM), terapia estrogênica isolada ou associada a progestágenos. A publicação de estudos controlados, randomizados, como o Heart and Estrogen/progestin Replacement Study (HERS) e Women’s Health Initiative (WHI), intensificou essa controvérsia risco/benefício. Milhares de mulheres são tratadas com THM para alívio dos sintomas menopausais, incluindo sintomas vasomotores e sudorese, principal indicação da estrogenoterapia. Outras p...
Source: Arquivos Brasileiros de Endocrinologia e Metabologia - May 14, 2014 Category: Endocrinology Source Type: research

Current recommendations: what is the clinician to do?
Menopausal hormone therapy (HT) has complex biologic effects but continues to have an important clinical role in the management of vasomotor and other menopausal symptoms. The rational use of menopausal HT requires balancing the potential benefits and risks of treatment. Findings from the Women's Health Initiative (WHI) and other randomized clinical trials have helped to clarify the benefits and risks of HT and have provided insights to improve decision making. Several clinical characteristics have utility in identifying women for whom benefits of HT are likely to outweigh the risks. Age and time since menopause are strong...
Source: Fertility and Sterility - March 31, 2014 Category: Reproduction Medicine Authors: JoAnn E. Manson Tags: Views and reviews Source Type: research

Cardiovascular benefits of HRT may differ by patient age
Commentary on: Main C, Knight B, Moxham T, et al.. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev 2013;(4):CD002229. Context In early postmenopausal women oestrogen and/or hormone replacement therapy (ERT/HRT) are used to alleviate symptoms and reduce the probability of diseases related to ovarian hormones deprivation. However, in late postmenopausal women the initiation of HRT has a negative risk/benefit balance mainly because of the increased risk of cardiovascular diseases (CVD). Methods Main et al performed a meta-analysis of randomised controlled trials (RCTs...
Source: Evidence-Based Medicine - March 19, 2014 Category: Internal Medicine Authors: Rosano, G., Vitale, C. Tags: Clinical trials (epidemiology), Epidemiologic studies, Drugs: cardiovascular system, Stroke, Contraception, Drugs: obstetrics and gynaecology, Menopause (including HRT), Interventional cardiology, Ischaemic heart disease, Venous thromboembolism, Radiology Source Type: research

Moderate Exercise Cuts Women's Stroke Risk, Helps Offset Increase Risk from Hormone Therapy
Source: American Heart Association Related MedlinePlus Pages: Hormone Replacement Therapy, Stroke
Source: MedlinePlus Health News - February 14, 2014 Category: Consumer Health News Source Type: news

Exercise Cuts Stroke Risk From Hormone Therapy (CME/CE)
(MedPage Today) -- Exercise may moderately shave off some of the increased risk of hormone therapy, researchers found.
Source: MedPage Today OB/GYN - February 13, 2014 Category: OBGYN Source Type: news

Association of Ischemic Stroke, Hormone Therapy, and Right to Left Shunt in Postmenopausal Women
Conclusions Approximately 20% of older women have a right to left shunt. Hormone therapy in these women may increase the risk of ischemic stroke by promoting paradoxical embolism. © 2014 Wiley Periodicals, Inc.
Source: Catheterization and Cardiovascular Interventions - February 12, 2014 Category: Cardiovascular & Thoracic Surgery Authors: Nancy C. Greep, David S. Liebeskind, Rubine Gevorgyan, Tam Truong, Bennett Cua, Chi‐Hong Tseng, David W. Dodick, Bart M. Demaerschalk, David E. Thaler, Jonathan M. Tobis Tags: Original Studie Source Type: research

Impact of methodology on estrogens' effects on cerebral ischemia in rats: an updated meta-analysis
Conclusions: We conclude that the discordant results regarding estrogens' effects in rat models of ischemic stroke are a consequence of differences in estrogen administration modes. These results are not only of importance for the ongoing debate regarding menopausal hormone therapy, but also have an important bearing on experimental stroke methodology and the apparent translational roadblock for suggested stroke interventions.
Source: BMC Neuroscience - Latest articles - February 4, 2014 Category: Neuroscience Authors: Jakob StrömEdvin Ingberg Source Type: research

Hormone Therapy in Women After Heart Transplantation
Conclusions: HT is not associated with poor outcome or adverse effects in female heart transplant patients after age 35 years. However, a larger cohort of patients is necessary to confirm these observations.
Source: Transplantation Proceedings - November 1, 2013 Category: Transplant Surgery Authors: L.C. Kobashigawa, M. Hamilton, M. Rafiei, L. Stern, C.N. Bairey Merz Tags: Thoracic Transplantation Source Type: research

Child abuse is related to inflammation in mid-life women: Role of obesity.
CONCLUSION: A history of childhood abuse and neglect retrospectively reported is related to overall elevated inflammation in mid-life women, perhaps through obesity. A history of some types of abuse and neglect (emotional) may be related to change in inflammation, independent of simultaneously measured change in BMI. PMID: 24076375 [PubMed - as supplied by publisher]
Source: Brain, Behavior, and Immunity - September 25, 2013 Category: Neurology Authors: Matthews KA, Chang YF, Thurston RC, Bromberger JT Tags: Brain Behav Immun Source Type: research

Different risks for heart attack and stroke posed by different hormone therapy formulations
Post-menopausal women whose doctors prescribe hormone replacement therapy for severe hot flashes and other menopause symptoms may want to consider taking low doses of Food and Drug Administration-approved bioidentical forms of estrogen or getting their hormones via a transdermal patch. A new observational study shows bioidentical hormones in transdermal patches may be associated with a lower risk of heart attack and FDA-approved products -- not compounded hormones -- may be associated with a slightly lower risk of stroke compared to synthetic hormones in pill form...
Source: Health News from Medical News Today - September 20, 2013 Category: Consumer Health News Tags: Menopause Source Type: news